ORGO Q4 2020 Earnings — Organogenesis Holdings Inc. Revenue & Financial Results | Market Cap Arena

ORGOOrganogenesis Holdings Inc.

$355M

Q4 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$107M+43.1% YoY

Gross Profit

$81M76.1% margin

Operating Income

$22M20.4% margin

Net Income

$18M17.3% margin

EPS (Diluted)

$0.15

QoQ Revenue Growth

+6.0%

Cash Flow

Operating Cash Flow

$26M

Free Cash Flow

$17M

Stock-Based Comp.

$497,000

Balance Sheet

Total Assets

$290M

Total Liabilities

$148M

Stockholders' Equity

$142M

Cash & Equivalents

$84M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$107M	$75M	+43.1%
Gross Profit	$81M	$54M	+49.8%
Operating Income	$22M	-$2M	+1341.2%
Net Income	$18M	-$4M	+520.5%

Revenue Segments

Advanced Wound care

$94M88%

Surgical and Sports Medicine

$13M12%